Tandem Diabetes Care Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers
12 Dicembre 2023 - 10:15PM
Business Wire
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, today announced the
launch of Tandem Source, a diabetes management platform for insulin
pump users and healthcare providers (HCPs). Tandem Source is
designed to bring together the features of Tandem’s legacy
t:connect, t:connect HCP, and t:connect Portal offerings with new
comprehensive data reporting in one central, scalable platform.
Tandem Source is now available for all Tandem pump users and their
HCPs in the United States, with international availability expected
in 2024.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231212863199/en/
Tandem Source, a new diabetes management
platform for insulin pump users and healthcare providers, now
available for all Tandem Diabetes Care customers in the United
States. (Photo: Business Wire)
“The launch of Tandem Source offers new, easy-to-use reports and
the consolidation of several platforms and features into a single,
convenient location for all our customers’ needs,” said John
Sheridan, president and CEO of Tandem Diabetes Care. “Feedback from
early adopters of Tandem Source in the United States has been
overwhelmingly positive, and we look forward to expanding access to
other countries in the coming year.”
Tandem Source provides access to important therapy data as well
as convenient ways for pump users to reorder supplies and update
their pump software. For HCPs, Tandem Source provides the tools
necessary to seamlessly view critical patient data, identify trends
and help their patients better manage their diabetes. Both HCPs and
pump users also have access to three new Tandem Source reports in
the platform.
Tandem Source Highlights:
- A new web-based pump uploader offers faster data transfers to
the cloud with no computer software to install or update.
- Automatic data transfers from users’ pumps using the t:connect
mobile app keep online data current and remove the need for manual
pump uploads.1
- Three easy-to-use reports consolidate all the information
needed for HCPs to make impactful clinical recommendations.
Tandem Source is now available to all Tandem insulin pump users
and HCPs based in the United States. Those who currently use the
t:connect Portal or t:connect HCP will have their data
automatically transferred to Tandem Source and will be able to use
their existing login credentials. For more information, please
visit http://www.tandemdiabetes.com/tandem-source.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a global insulin delivery and
diabetes technology company based in San Diego, California, creates
new possibilities for people living with diabetes, their loved
ones, and healthcare providers through a positively different
experience. The company’s human-centered approach to design,
development, and support delivers innovative products and services
for people who use insulin. Tandem manufactures and sells the
t:slim X2 insulin pump with Control-IQ technology. For more
information, visit tandemdiabetes.com.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2 and #TandemDiabetes. Follow Tandem Diabetes Care on
Facebook at facebook.com/TandemDiabetes. Follow Tandem Diabetes
Care on LinkedIn at linkedin.com/company/tandemdiabetes.
Important Safety Information
The Tandem Source platform is intended for use by individuals
with diabetes mellitus who use Tandem Diabetes Care insulin pumps,
their caregivers, and their healthcare providers in home and
clinical settings. The Tandem Source platform supports diabetes
management through the display and analysis of information uploaded
from Tandem insulin pumps.
Forward-looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements relate to, among other
things, the anticipated international launch of the Tandem Source
platform in 2024. These forward-looking statements are subject to
numerous risks and uncertainties, including the risks associated
with the research and development process generally, such as the
design, testing, and validation in compliance with the applicable
regulatory and legal requirements in the markets that we serve as
well as our ability to develop, scale, and maintain systems,
personnel, and infrastructure necessary to support customers across
diverse geographies and market segments. These and other risks are
identified and described in greater detail under the “Risk Factors”
heading of our most recent Annual Report on Form 10-K. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Actual
results could differ materially from those anticipated or projected
in the forward-looking statements. Tandem undertakes no obligation
to update or review any forward-looking statement in this press
release because of new information, future events, or other
factors.
© 2023 Tandem Diabetes Care, Inc. All rights reserved. Tandem
Diabetes Care, the Tandem logo, Tandem Source, Control-IQ, and
t:slim X2 are either registered trademarks or trademarks of Tandem
Diabetes Care, Inc. in the United States and/or other countries.
All third-party marks are the property of their respective
owners.
1 The information on the t:connect mobile app display may not be
identical to the current status of the user’s pump. Wireless
uploads from the t:connect mobile app to the cloud-based Tandem
Source platform require a compatible phone and an internet or
wireless data connection. Uploads to the Tandem Source platform do
not take place in real time and should not be relied upon by
healthcare providers or caregivers for remote patient monitoring.
Standard carrier data rates may apply.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231212863199/en/
Media Contact: 858-366-6900 media@tandemdiabetes.com
Investor Contact: 858-366-6900 IR@tandemdiabetes.com
Grafico Azioni Tandem Diabetes Care (NASDAQ:TNDM)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Tandem Diabetes Care (NASDAQ:TNDM)
Storico
Da Set 2023 a Set 2024